Fidelity Investments
VVOS icon

Fidelity Investments’s Vivos Therapeutics VVOS Stock Holding History

Fidelity Investments’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40
Closed -$124 – 5613
2025
Q3 		$124 Buy
+40
New +$181 ﹤0.01% 5192
2023
Q2 		– Sell
-144
Closed -$1.23K – 5609
2023
Q1 		$1.23K Buy
+144
New +$3.15K ﹤0.01% 4714
2022
Q3 		– Hold
0
– – – 5455
2022
Q2 		– Hold
0
– – – 5527

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AWA
Acorn Wealth Advisors Grand Blanc, Michigan $343M AUM 15.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments's VVOS Position: Q4 2025 in Review

Fidelity Investments sold out of Vivos Therapeutics (VVOS) in Q4 2025, closing a stake of 40 shares — an estimated $124 sold.

Fidelity Investments first reported a position in VVOS in Q1 2023 and held it in 2 quarters. The position peaked at $1.23K in Q1 2023. 19 funds tracked by Wall St. Rank hold VVOS as of Q4 2025.

  • Fidelity Investments reported no remaining Vivos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fidelity Investments sold 40 Vivos Therapeutics shares in Q4 2025, an estimated $124.
  • Fidelity Investments first reported a position in Vivos Therapeutics in Q1 2023 and held it in 2 quarters.
  • Fidelity Investments's Vivos Therapeutics position peaked at $1.23K in Q1 2023.
  • 19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2025.

Based on Fidelity Investments's 13F filing for Q4 2025, filed 17 Feb 2026.